Myomo (MYO) Asset Writedowns and Impairment (2017 - 2025)

Myomo's (MYO) quarterly Asset Writedowns and Impairment came in at $103779.0 in Q3 2025, up 100.95% on a QoQ basis from $51643.0 in Q1 2025.

Myomo (MYO) Asset Writedowns and Impairment (2017 - 2025) Analysis & Trends

Myomo (MYO) has 8 years of Asset Writedowns and Impairment data on file, last reported at $103779.0 in Q3 2025.

Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $103779.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $193822.0 (up 821.56% YoY) and the FY2024 annual result came in at $43657.0, up 53.72% from the prior year.
Asset Writedowns and Impairment rose to $103779.0 in Q3 2025, from $51643.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $103779.0 in Q3 2025 to a low of -$374.0 in Q3 2023.
A 4-year average of $31694.4 and a median of $20925.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment sank 50.14% — and 2024, when it soared 143.42%.
Tracing MYO's Asset Writedowns and Impairment over 4 years: stood at $26075.0 in 2022, then tumbled by 39.5% to $15775.0 in 2023, then soared by 143.42% to $38400.0 in 2024, then surged by 170.26% to $103779.0 in 2025.
The last three Asset Writedowns and Impairment figures came in at $103779.0 (Q3 2025), $51643.0 (Q1 2025), and $38400.0 (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	199.07 Bn	193.46 Bn	7.27 Bn
2	Stryker	127.90 Bn	124.43 Bn	4.50 Bn
3	Medtronic	118.84 Bn	109.62 Bn	6.41 Bn
4	Boston Scientific	73.33 Bn	72.79 Bn	3.85 Bn
5	Edwards Lifesciences	51.93 Bn	47.68 Bn	1.35 Bn
6	Dexcom	34.46 Bn	32.51 Bn	830.00 Mn
7	GE HealthCare Technologies	33.91 Bn	31.81 Bn	2.18 Bn
8	Koninklijke Philips	26.36 Bn	23.04 Bn	4.55 Bn
9	Steris	23.12 Bn	22.64 Bn	684.20 Mn
10	Myomo	72.11 Mn	53.14 Mn	-

Download Data